Education
About Us
Working with TipRanks
Follow Us
Biomea Fusion (BMEA)
NASDAQ:BMEA
BMEA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.35 - $16.29
Previous CloseN/A
Volume309.16K
Average Volume (3M)612.62K
Market Cap
$91.32M
Enterprise Value$287.44M
Total Cash (Recent Filing)-$239.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Apr 30, 2025EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding36,238,686
10 Day Avg. Volume710,199
30 Day Avg. Volume612,615
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap3.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-68.42
Enterprise Value/Ebitda-1.92
Forecast
1Y Price Target
$21.40Price Target Upside759.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Biomea Fusion News
PremiumCompany Announcements
Biomea Fusion Appoints Interim CEO Amid Leadership Changes
PremiumPre-Earnings
Is BMEA a Buy, Before Earnings?---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive topline results from the Phase 2 COVALENT-111 clinical trial evaluating icovamenib in patients with T2D were announced.
Drug Mechanism And EfficacyIcovanemib's proposed mechanism of action leads to a persistent increase in C-peptide levels, suggesting restoration of endogenous insulin production and enhanced β-cell function.
Synergy With Other TreatmentsThe potential synergy with icovamenib may allow for improved efficacy for patients, lower doses of GLP-1RAs to achieve glycemic and weight loss targets, and reduced side effects.
Bears Say
Market ChallengesThe evolution of next-generation GLP-1 RAs should focus on improving efficacy profiles and overcoming side effects, product shortages, and costs of manufacturing associated with current GLP-1 drugs.
---
Ownership Overview
17.81% Insiders
14.89% Mutual Funds
21.50% Other Institutional Investors
37.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $2.35 and its highest was $16.29 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $91.32M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Apr 30, 2025 which is in 32 days.
How were Biomea Fusion’s earnings last quarter?
Currently, no data Available
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -0.92.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 36,238,686 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biomea Fusion?
Currently, no hedge funds are holding shares in BMEA
---
Biomea Fusion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.40 (759.44% Upside)
$21.40 (759.44% Upside)
Blogger Sentiment
Bullish
BMEA Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 575.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.78%
12-Months-Change
Fundamentals
Return on Equity
-104.51%
Trailing 12-Months
Asset Growth
-50.94%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
---
BMEA Stock 12 Month Forecast
Average Price Target
$21.40
▲(759.44% Upside)
Technical Analysis
Best Analysts Covering BMEA
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-7.63%
reiterated a buy rating 5 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -7.63% per trade.
---